Overview
Berkeley Lights provides an integrated platform for accelerating cell-based research across biopharma, cellular therapy, and genomics. Its platform combines OptoSelect chips, automation hardware, and specialized software to perform high-throughput single-cell analysis by using optofluidics to manipulate thousands of cells in parallel. It stands out by offering an end-to-end solution—hardware, consumables, and software designed to work together for fast, precise cell analysis and development. The company's goal is to help customers discover therapies faster by delivering more accurate data on individual cells.
Work here?Claim your company
Simplify's take
What believers are saying
- Bruker Cellular Analysis launched Beacon Discovery cell line development in November 2026.
- Bruker still markets Beacon and publishes 2026 customer wins, signaling commercial traction.
- PEGS Europe 2026 and new webinars show active demand generation and product investment.
What critics are saying
- Berkeley Lights ceased independence after Bruker's October 2023 acquisition, shrinking career upside.
- Bruker could prioritize higher-return groups, cutting Beacon headcount and budgets in 2027.
- Single-cell competitors like 10x Genomics and IsoPlexis-derived workflows pressure Beacon adoption timelines.
What makes Berkeley Lights unique
- Bruker inherited Berkeley Lights' Beacon optofluidic platform, still sold in November 2026.
- Beacon Discovery compresses single-cell functional analysis into a benchtop workflow for 2026 labs.
- Its installed base spans antibody discovery, T-cell profiling, and cell line development globally.
Help us improve and share your feedback! Did you find this helpful?